Effect of piroxicam administration in infertile women undergoing assisted reproductive technologies: A systematic review and meta-analysis.

Aboshama, Rehab Abdelhamid; Islam, Bassem Aly; Motaal, Ahmed Osama Abdel; Labib, Kareem; Mohamed Hegab, Amr Salah; Abdelhakim, Ahmed Mohamed; Abbas, Ahmed M.; Saleh, Doaa M.

To evaluate piroxicam effect on different pregnancy outcomes among infertile women undergoing assisted reproductive technologies (ART). We searched for the available randomized clinical trials (RCTs) in four different databases during January 2021 that compared piroxicam (intervention group) to placebo/no treatment (control group) in infertile women performing ART. We extracted the available data from included studies and pooled them in a meta-analysis model using RevMan software. We pooled the dichotomous data as risk ratios (RR) with the corresponding 95% confidence intervals (CI) using RevMan software. Our outcomes were rates of clinical pregnancy, ongoing pregnancy, miscarriage, and any adverse events. Seven RCTs met our inclusion criteria with a total number of 1226 patients. Piroxicam was linked to a significant increase in clinical pregnancy rate compared to control group (RR = 1.30, 95% CI [1.09, 1.55], p =.003). However, we did not report any significant difference between both groups in ongoing pregnancy rate (RR = 1.27, 95% CI [0.72, 2.24], p =.41). In addition, the rates of miscarriage and adverse events were not different among both groups. Piroxicam administration increases the clinical pregnancy rate among infertile women. However, piroxicam does not affect miscarriage and ongoing pregnancy rates

REPRODUCTIVE technology; PIROXICAM; PREGNANCY outcomes; CLINICAL trials; MISCARRIAGE

Gynecological Endocrinology, 2021, Vol 37, Issue 9, p785

0951-3590

Academic Journal

10.1080/09513590.2021.1900818